DanDi Bioscience

https://www.businesspost.co.kr/BP?command=article_view&num=283299  

This post has been translated from the original article dated 6/8/2022. 

▲ Park Young-min, CEO of HLB Science, attends an online company briefing held on the 8th and explains the current status of the business.

[Business Post] Park Young-min, CEO of HLB Science, predicted that clinical preparations for sepsis treatment would soon be completed.

CEO Park attended the HLB Science company briefing held online on the 8th and said, “The final work of preparing (filing) documents for the clinical trial plan (IND) for sepsis treatment is almost finished.” revealed

CEO Park added, “After submitting the data, it is expected to enter phase 1 clinical trials after an evaluation for about 2 to 3 months.”

Phase 1 clinical trials for sepsis treatment were expected to be completed within 2023 at the earliest. CEO Park saw the possibility of promoting technology exports to large pharmaceutical bio companies at home and abroad after the completion of phase 1 clinical trials. He added that there are companies that he is still in contact with regarding technology exports.

HLB Science, an affiliate of the HLB Group, is developing sepsis treatment and Alzheimer's disease treatment based on technology that neutralizes endotoxin possessed by bacteria while removing pathogens.

The development of a treatment for Alzheimer's disease is progressing at a level that is about a year behind compared to a treatment for sepsis. It is also developing its own dementia diagnosis kit to xxxselect targets for treatment.

Research on new diseases such as non-alcoholic fatty liver disease is also being promoted. CEO Park said, "We have set a target for cooperation (for non-alcoholic fatty liver disease)."

CEO Park said that he would make efforts to list HLB Science in 2023 in relation to the KOSDAQ transfer listing. Currently, HLB Science is listed on KONEX, and Shinhan Investment Corp. was xxxselected as the representative manager for the transfer listing in April. Reporter Lim Han-sol